AKBA Probiotic Composition Modulates Gut Microbiome for Asthma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic asthma and inflammation lack effective and side-effect-reduced solutions, and there is a need for improved methods to modulate the gut microbiome for therapeutic benefits such as weight management.
Innovation Solution
Administration of a composition containing 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or Boswellia serrata extract, combined with live or lyophilized probiotic bacteria, specifically increasing the ratio of Bifidobacterium pseudolongum in the gut microbiome to treat allergic pulmonary inflammation and support weight loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for allergic asthma are used, then inflammation is suppressed, but side effects increase and effectiveness is limited
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus casei, Bifidobacterium animalis, Streptococcus thermophilus) as intermediary agents that mediate the therapeutic effect. These probiotics serve as living carriers that deliver anti-inflammatory compounds to the gut microbiome, which then indirectly modulates pulmonary inflammation through the gut-lung axis, reducing direct exposure to harsh anti-inflammatory drugs and their side effects
Solution Approach 2:
The probiotic bacteria perform self-service by naturally colonizing the gut and producing their own anti-inflammatory metabolites (short-chain fatty acids, bacteriocins). The gut microbiome itself becomes the therapeutic agent, self-regulating inflammation through its metabolic activities without requiring continuous external drug administration
2Reliability
If gut microbiome modulation is implemented, then therapeutic benefits are achieved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic functions into a single probiotic composition. The probiotic bacteria simultaneously provide immunomodulation, produce anti-inflammatory metabolites, and restore gut microbiome balance. This combination approach consolidates what would otherwise require multiple separate treatments into one unified therapy
Solution Approach 2:
The probiotic composition exhibits multi-functionality by addressing both local gut health and distant pulmonary inflammation through the gut-lung axis. The same probiotic agents perform multiple roles: colonizing the gut, producing metabolites, modulating immunity, and reducing asthma symptoms, making the treatment universally applicable to various aspects of the disease
Data Source
AI summary
A gut microbiome may be modulated in a patient in need thereof, by administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient; wherein the composition is administered at a dose sufficient to change the ratio between a first organism in the gut microbiome and a second organism in the gut microbiome, compared to a subject not treated with the composition. Modulation of the gut microbiome with AKBA may be used to treat allergic pulmonary inflammation in the patient. Modulation of the gut microbiome with AKBA may be used to maintain diversity and/or increase a percentage of Bifidobacterium pseudolongum in the gut microbiome of the patient. The composition may further comprise a lyophilized probiotic bacteria. The composition may be administered in combination with a second composition comprising a lyophilized probiotic bacteria.